[go: up one dir, main page]

CA2223489A1 - Procedes de traitement de cancers a l'aide de 6-¬3-¬1-adamantyl|-4-hydroxyphenyl| - Google Patents

Procedes de traitement de cancers a l'aide de 6-¬3-¬1-adamantyl|-4-hydroxyphenyl| Download PDF

Info

Publication number
CA2223489A1
CA2223489A1 CA002223489A CA2223489A CA2223489A1 CA 2223489 A1 CA2223489 A1 CA 2223489A1 CA 002223489 A CA002223489 A CA 002223489A CA 2223489 A CA2223489 A CA 2223489A CA 2223489 A1 CA2223489 A1 CA 2223489A1
Authority
CA
Canada
Prior art keywords
ahpn
cells
cell
mda
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002223489A
Other languages
English (en)
Inventor
Joseph A. Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2223489A1 publication Critical patent/CA2223489A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procédés de traitement ou de prévention du cancer du sein ou de la leucémie chez des sujets nécessitant un traitement, qui consistent à administrer de l'acide carboxylique de 6-[3-[1-adamantyl]-4-hydroxyphényl]-2-naphtalène, un rétinoïde qui induit l'arrêt G¿0?/G¿1? et l'apoptose. Lesdits procédés sont utiles pour le traitement des cancers du sein qui expriment ou n'expriment pas les récepteurs d'oestrogène.
CA002223489A 1995-07-17 1996-07-17 Procedes de traitement de cancers a l'aide de 6-¬3-¬1-adamantyl|-4-hydroxyphenyl| Abandoned CA2223489A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US146595P 1995-07-17 1995-07-17
US60/001,465 1995-07-17

Publications (1)

Publication Number Publication Date
CA2223489A1 true CA2223489A1 (fr) 1997-02-06

Family

ID=21696159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223489A Abandoned CA2223489A1 (fr) 1995-07-17 1996-07-17 Procedes de traitement de cancers a l'aide de 6-¬3-¬1-adamantyl|-4-hydroxyphenyl|

Country Status (5)

Country Link
EP (1) EP0850067A4 (fr)
JP (1) JP2000506489A (fr)
AU (1) AU701790B2 (fr)
CA (1) CA2223489A1 (fr)
WO (1) WO1997003682A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739557B1 (fr) 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
WO1998001132A1 (fr) * 1996-07-08 1998-01-15 Centre International De Recherches Dermatologiques Galderma Derives d'adamantyle induisant l'apoptose et leur utilisation comme agents anticancereux
DE60022207T2 (de) 1999-08-31 2006-06-22 Incyte San Diego Incorporated, San Diego Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
WO2002072543A2 (fr) 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Molecules activant un recepteur rxr
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1456187A4 (fr) 2001-11-15 2005-02-09 Incyte San Diego Inc Heterocycles n-substitues pour le traitement de l'hypercholesterolemie, de la dyslipidemie et autres troubles du metabolisme, du cancer et de pathologies diverses
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US20060151574A1 (en) * 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
WO2007148804A1 (fr) * 2006-06-23 2007-12-27 Rohto Pharmaceutical Co., Ltd. Composition capable de favoriser la production d'acide hyaluronique
EP3301085A1 (fr) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Derives de retinoïde a activite antitumorale
WO2022229017A1 (fr) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Dérivé adamantylique de rétinoïde présentant une activité anticancéreuse

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques

Also Published As

Publication number Publication date
AU701790B2 (en) 1999-02-04
JP2000506489A (ja) 2000-05-30
WO1997003682A1 (fr) 1997-02-06
EP0850067A1 (fr) 1998-07-01
EP0850067A4 (fr) 1999-12-15
AU6494996A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
AU701790B2 (en) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
Reynolds et al. Retinoid therapy of childhood cancer
US6130230A (en) Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
Supino et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression
Soprano et al. Retinoids as teratogens
US12297173B2 (en) Compounds and methods for inhibiting CYP26 enzymes
US20090093546A1 (en) Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators
Zhu Vitamin A and its derivatives-retinoic acid and retinoid pharmacology
US6211239B1 (en) Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
Hu et al. Retinoid treatment for oral leukoplakia: current evidence and Future Development
Makishima et al. Induction of differentiation in acute promyelocytic leukemia cells by 9-cis retinoic acid α-tocopherol ester (9-cis tretinoin tocoferil)
WO2008022505A1 (fr) Utilisation de rubescensine a et de ses dérivés en pharmacie
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
WO2001078700A2 (fr) Compositions et procedes utilises pour moduler la fonction du systeme immunitaire
Muñiz-Hernández et al. Alterations in retinoic acid receptors in non-small cell lung cancer and their clinical implications
CA2558199C (fr) Procede de prevention de la proliferation de l'epithelium pigmentaire de la retine au moyen d'agonistes du recepteur acide retinoique
Tsiklakis et al. The therapeutic effect of an aromatic retinoid (RO-109359) on hamster buccal pouch carcinomas
HUP0400255A2 (hu) Retinoid receptor ligandumok és kiválasztott citotoxikus szerek szinergikus kombinációi rák kezelésére
JP3824422B2 (ja) レチノイン酸の活性増強剤
Tohda et al. The effects of retinoic acid analogs on the blast cells of acute myeloblastic-leukemia in culture
Wu Critical role for retinoid nuclear receptors RAR and RXR in determining the sensitivity of human ovarian cancer cell lines to retinoid treatment
JPH1072345A (ja) ９−シス−レチノイン酸−α−トコフェロールエステルを含有する白血病治療剤
AU2002305072A1 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
Chomienne Molecular Basis for Retinoic Acid Effects in Acute Promyelocytic Leukemia
Chapman Molecular Mechanism of Action of the Synthetic Retinoid N-(4-hydroxyphenyl) retinamide

Legal Events

Date Code Title Description
FZDE Discontinued